Angiolink Corporation
Angiolink privately held medical device company focused on developing innovative wound closure solutions for vascular procedures
About Angiolink Corporation
Angiolink Corporation, established in 1999, was a privately held medical device company that focused on developing wound closure solutions for vascular procedures. Based in Taunton, Massachusetts, the company identified a critical need for safer and more efficient methods to close femoral artery access sites following catheter-based interventions like diagnostic angiography and stenting. This led to the development of its flagship product, the EVS™ (Expanding Vascular Stapling) Vascular Closure System.
The EVS system was engineered to provide an extraluminal closure of the femoral artery by applying a biocompatible titanium staple. This mechanical closure was designed to approximate the arteriotomy edges, promoting natural healing and significantly reducing the time to hemostasis and patient ambulation compared to traditional manual compression methods. The device consisted of a single-use, trigger-activated deployment tool and the staple itself, which remained sterile within the housing until application, minimizing the risk of contamination. The system was intended for use by physicians to close arterial punctures from 6F to 8F procedural sheaths.
Angiolink secured significant financial backing from investors including BioVentures Investors, JHK Investments, and IDP Investments, raising a total of $27.8 million over several funding rounds. A pivotal moment for the company occurred in late 2004 when it received FDA pre-market approval for the EVS system. Almost simultaneously, in November 2004, Angiolink was acquired by Medtronic, a global leader in medical technology. At the time of the acquisition, Angiolink employed 15 people and was poised to enter a vascular closure market estimated to be worth around $500 million. The acquisition integrated Angiolink's operations into Medtronic's Danvers, Massachusetts facility, leveraging Medtronic's scale to bring the EVS technology to a wider global market.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 17.0/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Surgery, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Sep 2003 | $14M | $54M | Bioventures Investors · Boston Financial & Equity Corporation · IDP Industrial Development Partners | — |
| SERIES A✓Equity / VC | Sep 2002 | $11M | $42M | Boston Financial & Equity Corporation · Bioventures Investors | — |
Growth signals
Latest recorded traffic for Angiolink Corporation is 0 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Angiolink Corporation in the Taunton ecosystem
The Angiolink Corporation office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- BIBioventures Investors
- BCBoston Financial & Equity Corporation
- IPIDP Industrial Development Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Angiolink Corporation on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Angiolink Corporation’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








